37
Participants
Start Date
June 30, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
clevidipine
"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
Columbia University Medical Center, New York
Thomas Jefferson University Stroke Research, Philadelphia
The John Hopkins Hospital, Baltimore
Guilford Neurologic - Moses H Cone Health System, Greensboro
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
The Ohio State University, Columbus
Cleveland Clinic Hospitals, Cleveland
Henry Ford Hospital, Detroit
Intermountain Medical Center, Murray
The Queens Medical Center, Honolulu
Washington Hospital Center, Washington D.C.
Maine Medical Center, Portland
The University Health Science Center at S.A., San Antonio
Universitätsklinikum Leipzig, Liebigstraße 22a
Universitatsklinikum Erlangen, Erlangen
Universitatsklinikum Heidelberg, Heidelberg
Lead Sponsor
The Medicines Company
INDUSTRY